Next report date
Report period
Q1 2024
EPS estimate
−0.20EUR
Revenue estimate
5.89 MEUR
−233.60 MEUR
159.67 MEUR
183.15 M
Om Sangamo Therapeutics, Inc.
Sektor
Bransch
VD
Alexander D. Macrae
Webbplats
Huvudkvarter
Richmond
Employees (FY)
405
Grundat
1995
FIGI
BBG000BG4C37
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
